NASDAQ:CAMP CAMP4 Therapeutics Q1 2026 Earnings Report $3.92 +0.08 (+2.08%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$3.94 +0.02 (+0.61%) As of 09/25/2026 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CAMP4 Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.21Beat/MissMissed by -$0.11One Year Ago EPSN/ACAMP4 Therapeutics Revenue ResultsActual Revenue$1.29 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACAMP4 Therapeutics Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateThursday, May 7, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CAMP4 Therapeutics Earnings HeadlinesCAMP4 Therapeutics Secures UK Authorization For CMP-002 Clinical Trial In SYNGAP1 DisorderSeptember 10, 2026 | rttnews.comCAMP4 Therapeutics Gets Clearance to Conduct Phase 1/2 Study for SYNGAP1-Related Disorder Treatment in UKSeptember 10, 2026 | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 27 at 1:00 AM | Decentralized Masters (Ad)CAMP4 Therapeutics Receives MHRA Authorization to Include UK Sites in Global Phase 1/2 Trial of CMP-002 for SYNGAP1-Related DisorderSeptember 10, 2026 | quiverquant.comQCAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related DisorderSeptember 10, 2026 | globenewswire.comCAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026September 8, 2026 | globenewswire.comSee More CAMP4 Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CAMP4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CAMP4 Therapeutics and other key companies, straight to your email. Email Address About CAMP4 TherapeuticsCAMP4 Therapeutics (NASDAQ:CAMP) is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases caused by insufficient expression of essential proteins. The company’s approach is designed to increase the body’s production of naturally occurring proteins by activating the transcription of specific genes, potentially addressing the underlying cause of disease rather than only treating symptoms. CAMP4’s technology platform uses RNA-based gene-activation therapeutics intended to target regulatory regions associated with disease-relevant genes. Its development programs are focused on conditions in which restoring or increasing expression of a functional gene product may provide a therapeutic benefit. The company’s lead program, CMP-CPS-001, is being developed for carbamoyl phosphate synthetase 1 deficiency, a rare inherited disorder that affects the urea cycle and can cause the accumulation of toxic ammonia in the blood. Based in Cambridge, Massachusetts, CAMP4 Therapeutics was established to advance programmable gene-control medicines for rare and other genetically driven diseases. The company is conducting preclinical and clinical development activities and has focused its initial efforts on rare disorders with significant unmet medical needs. Additional information about its broader pipeline and leadership is limited relative to more established biopharmaceutical companies.View CAMP4 Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
